| REVOLUTION MEDICINES |
| USA |
| Gesundheit |
| US76155X1000 / A2PYWG |
| 42Z (Frankfurt) / RVMD (NASDAQ) |
| FRA:42Z, ETR:42Z, 42Z:GR, NASDAQ:RVMD |
| - |
| https://www.revmed.com/ |
|
Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approximately 30% of human cancer diagnoses. Founded in 201..
>Volltext.. |
| 28716.24 Mio. EUR |
| 27444.07 Mio. EUR |
| - |
| -1174.61 Mio. EUR |
| -1176.54 Mio. EUR |
| -6.07 EUR |
| 375.06 Mio. EUR |
| 378.2 Mio. EUR |
| - |
| 6.59 |
| - |
| -84.14% |
| - |
| - |
| - |
| REVOLUTION MEDICINES, REVOLUTION MED |
| 01.06.26 |
|
||||
|